<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Intensive Care Med Exp</journal-id><journal-id journal-id-type="iso-abbrev">Intensive Care Med Exp</journal-id><journal-title-group><journal-title>Intensive Care Medicine Experimental</journal-title></journal-title-group><issn pub-type="epub">2197-425X</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26215814</article-id><article-id pub-id-type="pmc">4486645</article-id><article-id pub-id-type="publisher-id">50</article-id><article-id pub-id-type="doi">10.1186/s40635-015-0050-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>A randomized clinical trial of ascorbic acid in open abdominal aortic aneurysm repair</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Duffy</surname><given-names>Martin J</given-names></name><address><email>martin.duffy@qub.ac.uk</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>O&#x02019;Kane</surname><given-names>Cecilia M</given-names></name><address><email>c.okane@qub.ac.uk</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Stevenson</surname><given-names>Michael</given-names></name><address><email>m.stevenson@qub.ac.uk</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Young</surname><given-names>Ian S</given-names></name><address><email>i.young@qub.ac.uk</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Harkin</surname><given-names>Denis W</given-names></name><address><email>denis.harkin@belfasttrust.hscni.net</email></address><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Mullan</surname><given-names>Brian A</given-names></name><address><email>brian.mullan@belfasttrust.hscni.net</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>McAuley</surname><given-names>Daniel F</given-names></name><address><email>d.f.mcauley@qub.ac.uk</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><aff id="Aff1"><label/>Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, UK </aff><aff id="Aff2"><label/>Centre for Infection and Immunity, The Queen&#x02019;s University Belfast, First Floor, Health Sciences Building, 97 Lisburn Road, Belfast, BT9 7BL UK </aff><aff id="Aff3"><label/>Centre for Public Health, The Queen&#x02019;s University Belfast, Belfast, UK </aff><aff id="Aff4"><label/>Regional Vascular Surgery Unit, Royal Victoria Hospital, Belfast, UK </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>7</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>7</month><year>2015</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2015</year></pub-date><volume>3</volume><elocation-id>20</elocation-id><history><date date-type="received"><day>9</day><month>6</month><year>2014</year></date><date date-type="accepted"><day>24</day><month>3</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Duffy et al. 2015</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Open AAA repair is associated with ischaemia-reperfusion injury where systemic inflammation and endothelial dysfunction can lead to multiple organ injury including acute lung injury. Oxidative stress plays a role that may be inhibited by ascorbic acid.</p></sec><sec><title>Methods</title><p>A double blind, allocation concealed, randomized placebo-controlled trial was performed to test the hypothesis that a single bolus dose (2g) of intra-operative parenteral ascorbic acid would attenuate biomarkers of ischaemia-reperfusion injury in patients undergoing elective open AAA repair.</p></sec><sec><title>Results</title><p>Thirty one patients completed the study; 18 received placebo and 13 ascorbic acid. Groups were comparable demographically. Open AAA repair caused an increase in urinary Albumin:Creatinine Ratio (ACR) as well as plasma IL-6 and IL-8. There was a decrease in exhaled breath pH and oxygenation. Lipid hydroperoxides were significantly higher in the ascorbic acid group following open AAA repair. There were no other differences between the ascorbic acid or placebo groups up to 4 hours after removal of the aortic clamping.</p></sec><sec><title>Conclusions</title><p>Open AAA repair caused an increase in markers of systemic endothelial damage and systemic inflammation. Administration of 2g parenteral ascorbic acid did not attenuate this response and with higher levels of lipid hydroperoxides post-operatively a pro-oxidant effect could not be excluded.</p></sec><sec><title>Trial registration</title><p><ext-link ext-link-type="uri" xlink:href="http://www.controlled-trials.com/ISRCTN27369400">ISRCTN27369400</ext-link></p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Ascorbic Acid</kwd><kwd>Ichaemia-Reperfusion injury</kwd><kwd>Abdominal aortic aneurysm</kwd><kwd>Perioperative anaesthesia</kwd><kwd>Perioperative critical care</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Open Abdominal Aortic Aneurysm (AAA) repair necessitates the use of an aortic cross-clamp which causes an ischaemia-reperfusion injury to remote tissues which can lead to multiple organ dysfunction syndrome (MODS) including acute lung injury (ALI) and death [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p>Ischaemia-reperfusion injury is associated with an increase in oxidative stress through the accumulation of reactive oxygen species (ROS) which can up-regulate pro-inflammatory pathways contributing to remote organ dysfunction [<xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref>]. Lipid peroxidation is central in oxidative stress and can be measured using end products [<xref ref-type="bibr" rid="CR4">4</xref>]. Ischaemia leads to endothelial activation with increased expression of endothelial adhesion molecules [<xref ref-type="bibr" rid="CR5">5</xref>]. Reperfusion enhances this response and is associated with up-regulation of plasma cytokines [<xref ref-type="bibr" rid="CR6">6</xref>] and increased leucocyte interaction [<xref ref-type="bibr" rid="CR7">7</xref>]. Increased urinary albumin:creatinine ratio (ACR) has been associated with impaired endothelial-dependent vasodilation [<xref ref-type="bibr" rid="CR8">8</xref>], a surrogate measure of endothelial dysfunction [<xref ref-type="bibr" rid="CR9">9</xref>]. There is evidence of systemic endothelial dysfunction as measured by urinary albumin:creatinine ratio (ACR) in patients undergoing open AAA repair [<xref ref-type="bibr" rid="CR10">10</xref>] correlating with outcome from ALI in this setting [<xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref>]. In patients undergoing open AAA repair a rise in ACR measured 4 hours following induction of anaesthesia predicted those at risk of post-operative pulmonary dysfunction [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p>Pulse Wave Analysis (PWA) provides a bedside measure of systemic endothelial function and has been shown to independently predict mortality in the critically ill [<xref ref-type="bibr" rid="CR14">14</xref>]. Pulmonary dead-space fraction is increased in the acute respiratory distress syndrome (ARDS) and may reflect the extent of pulmonary endothelial dysfunction [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p>Ascorbic acid can act as a reactive oxygen species (ROS) scavenger [<xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR17">17</xref>]. Low ascorbic acid levels have been described in humans subjected to ischaemia-reperfusion injury during cardiac surgery [<xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref>] and are associated with acute inflammation [<xref ref-type="bibr" rid="CR20">20</xref>]. Ascorbic acid attenuates endothelial dysfunction in animal models of acute lung injury (ALI) [<xref ref-type="bibr" rid="CR21">21</xref>] a condition characterized by uncontrolled inflammation [<xref ref-type="bibr" rid="CR22">22</xref>]. Ascorbic acid can improve endothelial function [<xref ref-type="bibr" rid="CR23">23</xref>] by inhibiting apoptosis [<xref ref-type="bibr" rid="CR24">24</xref>], and preserving endothelial barrier function [<xref ref-type="bibr" rid="CR25">25</xref>]. As a scavenger it reduces oxidative uncoupling of endothelial nitric oxide synthase (eNOS) leading to further ROS production [<xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR27">27</xref>]. The hypothesis in this study was that an intra-operative bolus dose (2g) of parenteral ascorbic acid may attenuate markers of oxidative stress, inflammation and endothelial dysfunction caused by open AAA repair.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><p>This was a single centre, double blind allocation concealed, randomized placebo-controlled trial. The protocol was approved by the local institution, the UK Medicines and Healthcare products Regulatory Agency and the regional ethics committee. Written informed consent was obtained from each participant prior to study commencement. The trial is registered with <ext-link ext-link-type="uri" xlink:href="http://www.isrctn.com">www.isrctn.com</ext-link> (ISRCTN27369400).</p><p>The study was performed at the Royal Victoria Hospital, Belfast, a tertiary care teaching hospital. Adults undergoing elective open AAA repair were eligible for enrollment. Exclusion criteria were age less than 18 years old, a history of hyperoxaluria or glucose-6-phosphate dehydrogenase deficiency, prior antioxidant therapy, known allergy to ascorbic acid or to anaesthetic agents specified in anaesthetic protocol, participation in another intervention trial within 30 days or a lack of consent.</p><p>Patients were randomly assigned to receive intraoperative intravenous ascorbic acid 2 g in 250 ml 0.9% saline or 250 ml 0.9% saline placebo over 15 minutes following induction of anaesthesia. Block randomization was performed by an independent statistician. The randomization assignments were concealed in sealed, tamper-proof envelopes that were opened sequentially by an independent pharmacist. When an eligible subject was recruited, the pharmacist allocated the subject to the designated treatment group, maintaining blinding. Ascorbic acid and 0.9% saline were prepared by the independent pharmacist and had an identical appearance. All staff and participants were blinded to treatment allocation.</p><sec id="Sec3"><title>Data collection</title><p>Baseline demographic data were collected including medical history. All participants underwent transperitoneal open AAA repair via midline laparotomy. Anaesthesia was provided via a standardized technique.</p><p>A summary of events and measurements performed is shown in Figure <xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Figure 1</label><caption><p>Summary of study period events and measurements. PWA &#x02013; Pulse Wave Analysis, PDSF &#x02013; Pulmonary Dead-Space Fraction, PFR &#x02013; PaO<sub>2</sub>:FiO<sub>2</sub> Ratio, EBC &#x02013; Exhaled Breath Condensate.</p></caption><graphic xlink:href="40635_2015_50_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec4"><title>Measurements</title><p>Plasma and serum samples were obtained from arterial blood samples taken from the indwelling arterial catheter. Blood samples were centrifuged at 2000 rpm for 10 minutes at 10&#x000b0;C and then samples were frozen at -80&#x000b0;C until analysis. Urine samples were collected and frozen at -80&#x000b0;C until analysis.</p><p>Plasma Von Willebrand Factor (vWF) level was measured by ELISA as previously described [<xref ref-type="bibr" rid="CR11">11</xref>]. Soluble forms of Intercellular adhesion molecule (sICAM)-1, vascular cell adhesion molecule (sVCAM)-1, endothelial (sE)-Selectin and platelet (sP)-Selectin were measured using a Fluorokine&#x000ae; MAP multiplex kit (R&#x00026;D Systems, Minneapolis, MN, USA) with a BioRad BioPlex&#x02122; analyser (Luminex Corp., Austin, TX, USA). Interleukins IL-6 and IL-8 were measured using a cytometric bead array (R&#x00026;D Systems, Abingdon, UK) as previously described [<xref ref-type="bibr" rid="CR28">28</xref>]. Serum highly sensitive C Reactive Protein (hsCRP) analysis was performed using the Quantex CRP ultra sensitive quantitative system (ILab Chemistry Systems, Instrumentation Laboratory Company, Lexington, Mass). Serum aqueous phase lipid hydroperoxides were measured using the ferrous iron/xylenol orange (FOX) assay as previously described [<xref ref-type="bibr" rid="CR29">29</xref>]. Plasma 8-iso-Prostaglandin F2&#x003b1; was measured using a direct enzyme immunoassay kit (Assay Designs Inc., Ann Arobor, Michigan, USA) with a BioRad BioPlex&#x02122; analyser (Luminex Corp., Austin, TX, USA). To measure plasma ascorbic acid, plasma was mixed with 5% meta-phosphoric acid (MPA) to stabilise ascorbic acid and then measured on a Cobas FARA centrifugal analyser with a fluorescent attachment according to Vuilleumier &#x00026; Keck [<xref ref-type="bibr" rid="CR30">30</xref>]. To determine urinary ACR, albumin was measured in urine using a commercially available immunoturbidimetric assay containing antibody specific for human albumin (Randox Laboratories Ltd. Crumlin, Co. Antrim, UK). Creatinine was measured using a modified Jaffe method as previously described (Roche Diagnostics, IN, USA) [<xref ref-type="bibr" rid="CR31">31</xref>].</p><p>PWA was used to assess systemic endothelial function as previously described [<xref ref-type="bibr" rid="CR14">14</xref>]. This was performed with the SphygmoCor Mx System (AtCor Medical, Sydney, Australia). An indwelling 20G radial arterial catheter was used to obtain a calibrated peripheral arterial pressure waveform. The central aortic waveform was derived from the peripheral arterial waveform using a validated transfer function [<xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR33">33</xref>]. Aortic augmentation is defined as the difference between the first systolic peak (caused by left ventricular contraction) and second systolic peak (caused by wave reflection) and the augmentation index (AIx) is this difference expressed as a percentage of the central pulse pressure. AIx is calculated and corrected to a heart rate to 75 beats/min. The AIx following nebulised salbutamol 2.5mg measures endothelium dependent vasodilation (EDV) [<xref ref-type="bibr" rid="CR34">34</xref>].</p><p>Pulmonary Dead-Space Fraction (Vd/Vt) was measured using volumetric capnography utilizing the NICO2 Monitor (Philips Respironics UK Ltd., Tangmere, UK) to calculate the partial pressure of expired CO<sub>2</sub>. This is then used in the Enghoff modification of the Bohr equation [<xref ref-type="bibr" rid="CR35">35</xref>]. This method has been validated in a cohort of patients with acute lung injury [<xref ref-type="bibr" rid="CR36">36</xref>].</p><p>Exhaled Breath Condensate (EBC) pH as a measure of alveolar neutrophilic inflammation was measured in EBC collected using an RTube&#x02122; (Respiratory Research, Austin, TX, USA) as previously described [<xref ref-type="bibr" rid="CR37">37</xref>]. Exhaled breath condensate pH was measured using an Orion 9803BN micro pH electrode and digital pH meter (Thermo Scientific, Waltham, MA, USA) immediately after collection.</p></sec><sec id="Sec5"><title>Statistics</title><p>Proportions were used as descriptive statistics for categorical variables. Mean (standard deviation) or median (interquartile range) were used as appropriate after testing for normality with the Kolmogorov-Smirnov test. Between group categorical variables were compared using Fishers exact test and continuous variables with an unpaired Student&#x02019;s <italic>t</italic>-test or Mann-Whitney <italic>U</italic> test as appropriate. Comparison of variables before and after open AAA repair was made using a paired Student&#x02019;s <italic>t</italic>-test or Wilcoxon matched pairs test as appropriate. Statistical analysis was performed and graphs generated using Prism 5 for Mac OS X, version 5.0b (GraphPad Software Inc.). A P value of &#x0003c;0.05 was considered significant.</p></sec><sec id="Sec6"><title>Power calculation</title><p>The sample size calculation was determined using data from a previous study examining plasma vWF concentration in elective open AAA repair patients [<xref ref-type="bibr" rid="CR12">12</xref>]. Based on these data, mean (standard deviation) vWF concentrations of 175(56) and 125(40) U/dl were assumed for patients receiving placebo and ascorbic acid respectively. On this basis 31 patients were required to complete the study. On the basis of assumed unequal variance between the groups, 18 patients were allocated to receive placebo and 13 to receive ascorbic acid. This provided 80% power to detect a statistical difference if the true difference was as suggested above. This calculation assumed that a two-tailed <italic>t</italic>-test at a 5% significance level was applied.</p></sec></sec><sec id="Sec7" sec-type="results"><title>Results</title><p>Forty three patients were screened over an 18 month period. Twelve patients were excluded. Thirty-one participants received study drug, completed the study and were included in the analysis. Thirteen patients received ascorbic acid and 18 received placebo (Figure <xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Figure 2</label><caption><p>Consort diagram of study recruitment.</p></caption><graphic xlink:href="40635_2015_50_Fig2_HTML" id="MO2"/></fig></p><p>Baseline characteristics were similar in both groups. The duration of ischaemic injury caused by the aortic clamp was similar between groups (Table <xref rid="Tab1" ref-type="table">1</xref>). Mean arterial pressure fell intra-operatively from 101 (17) mmHg to 85 (15) mmHg in the ascorbic acid group (p&#x02009;=&#x02009;0.03) and from 101 (16) mmHg to 82 (15) mmHg in the placebo group (p&#x02009;&#x0003c;&#x02009;0.001) but there were no differences between groups either pre- or post-operatively. Ascorbic acid levels measured four hours following removal of the aortic clamp were higher in the ascorbic acid group compared to placebo (104.4 (84.8, 132.7) &#x003bc;moll-1 vs 18.2 (6.2, 34.5) &#x003bc;moll-1, p&#x02009;&#x0003c;&#x02009;0.001).<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Demographic, historical and pre-operative physiological parameters</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th/><th>
<bold>Placebo group</bold>
</th><th>
<bold>Ascorbate group</bold>
</th></tr><tr valign="top"><th/><th>
<bold>n&#x02009;=&#x02009;18</bold>
</th><th>
<bold>n&#x02009;=&#x02009;13</bold>
</th></tr><tr valign="top"><th/><th>
<bold>Mean (SD), Median (IQR) or n (%)</bold>
</th><th>
<bold>Mean (SD), Median (IQR) or n (%)</bold>
</th></tr></thead><tbody><tr valign="top"><td>
<bold>Demographics</bold>
</td><td/><td/></tr><tr valign="top"><td>Age (years)</td><td>70.4 (7.4)</td><td>73.2 (5.9)</td></tr><tr valign="top"><td>Height (m)</td><td>1.71 (0.09)</td><td>1.71 (0.05)</td></tr><tr valign="top"><td>Weight (kg)</td><td>77.1 (11.1)</td><td>78.2 (7.7)</td></tr><tr valign="top"><td>BMI (kgm<sup>&#x02212;2</sup>)</td><td>26.4 (3.3)</td><td>26.8 (2.8)</td></tr><tr valign="top"><td>Gender (% male)</td><td>17 (94%)</td><td>11 (85%)</td></tr><tr valign="top"><td>
<bold>Past medical history</bold>
</td><td/><td/></tr><tr valign="top"><td>IHD</td><td>8 (44%)</td><td>4 (31%)</td></tr><tr valign="top"><td>Atrial Fibrillation</td><td>0 (0%)</td><td>2 (15%)</td></tr><tr valign="top"><td>Hypertension</td><td>16 (89%)</td><td>12 (92%)</td></tr><tr valign="top"><td>Cerebrovascular Disease</td><td>1 (6%)</td><td>1 (8%)</td></tr><tr valign="top"><td>
<bold>Cardiovascular risk factors</bold>
</td><td/><td/></tr><tr valign="top"><td>Smoking</td><td>4 (22%)</td><td>5 (38%)</td></tr><tr valign="top"><td>Hypercholesterolaemia</td><td>10 (56%)</td><td>6 (46%)</td></tr><tr valign="top"><td>Hypertension</td><td>16 (89%)</td><td>12 (92%)</td></tr><tr valign="top"><td>Diabetes</td><td>1 (6%)</td><td>0 (0%)</td></tr><tr valign="top"><td>
<bold>Drug history</bold>
</td><td/><td/></tr><tr valign="top"><td>Statin</td><td>12 (67%)</td><td>9 (69%)</td></tr><tr valign="top"><td>ACE Inhibitors</td><td>5 (28%)</td><td>3 (23%)</td></tr><tr valign="top"><td>&#x003b2; Blockers</td><td>7 (39%)</td><td>6 (46%)</td></tr><tr valign="top"><td>Diuretics</td><td>2 (11%)</td><td>3 (23%)</td></tr><tr valign="top"><td>Anticoagulants</td><td>5 (28%)</td><td>5 (38%)</td></tr><tr valign="top"><td>
<bold>Baseline physiological parameters</bold>
</td><td/><td/></tr><tr valign="top"><td>Respiratory Rate (min<sup>&#x02212;1</sup>)</td><td>14 (12,15)</td><td>12 (12,15)</td></tr><tr valign="top"><td>Temperature (&#x000b0;C)</td><td>36.6 (0.33)</td><td>36.8 (0.38)</td></tr><tr valign="top"><td>Heart Rate (min<sup>&#x02212;1</sup>)</td><td>63 (10.3)</td><td>60 (13.7)</td></tr><tr valign="top"><td>Peripheral SBP (mmHg)</td><td>145.2 (24.9)</td><td>150.5 (29.6)</td></tr><tr valign="top"><td>Peripheral DBP (mmHg)</td><td>77 (12.4)</td><td>76 (11.7)</td></tr><tr valign="top"><td>
<bold>Haematological and biochemical indices</bold>
</td><td/><td/></tr><tr valign="top"><td>Haemoglobin (gdl<sup>&#x02212;1</sup>)</td><td>13.7 (1.2)</td><td>13.7 (1.1)</td></tr><tr valign="top"><td>Leucocyte Count (x10<sup>9</sup>ml<sup>&#x02212;1</sup>)</td><td>7.3 (1.7)</td><td>7.3 (1.8)</td></tr><tr valign="top"><td>Platelet Count (x10<sup>9</sup>ml<sup>&#x02212;1</sup>)</td><td>201 (54)</td><td>211 (64)</td></tr><tr valign="top"><td>Urea (mmoll<sup>&#x02212;1</sup>)</td><td>7.8 (2.1)</td><td>6.7 (1.8)</td></tr><tr valign="top"><td>Creatinine (&#x003bc;moll<sup>&#x02212;1</sup>)</td><td>96 (31)</td><td>101 (30)</td></tr><tr valign="top"><td>
<bold>Surgical details</bold>
</td><td/><td/></tr><tr valign="top"><td>Ischaemic Time (mins)</td><td>60.5 (16.9)</td><td>64.6 (17.6)</td></tr></tbody></table><table-wrap-foot><p>SD, Standard Deviation, IQR, Interquartile Range, BMI, Body Mass Index, SBP, Systolic Blood Pressure, DBP, Diastolic Blood Pressure, IHD, Ischaemic Heart Disease, ACE, Angiotensin Converting Enzyme.</p></table-wrap-foot></table-wrap></p><sec id="Sec8"><title>Effects of ascorbic acid on endothelial function</title><p>Plasma VWF levels were similar between groups both before and after open AAA repair. Similarly there were no differences in EDV between groups either pre- or post-operatively (Table <xref rid="Tab2" ref-type="table">2</xref>). Urinary ACR was significantly higher in both the placebo (p&#x02009;&#x0003c;&#x02009;0.001) and ascorbic acid (p&#x02009;=&#x02009;0.01) groups after AAA repair, however there were no differences between the groups (Figure <xref rid="Fig3" ref-type="fig">3</xref>). There were no significant changes in pulmonary deadspace following open AAA repair (Table <xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Comparison of biomarkers in ascorbic acid and placebo groups pre- and post-operatively</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th/><th colspan="3">
<bold>Pre operative parameters</bold>
</th><th colspan="3">
<bold>Post operative parameters</bold>
</th></tr><tr valign="top"><th rowspan="4"/><th>
<bold>Placebo group</bold>
</th><th>
<bold>Ascorbate group</bold>
</th><th>
<bold>p-value</bold>
</th><th>
<bold>Placebo group</bold>
</th><th>
<bold>Ascorbate group</bold>
</th><th>
<bold>p-value</bold>
</th></tr><tr valign="top"><th>
<bold>n&#x02009;=&#x02009;18</bold>
</th><th>
<bold>n&#x02009;=&#x02009;13</bold>
</th><th/><th>
<bold>n&#x02009;=&#x02009;18</bold>
</th><th>
<bold>n&#x02009;=&#x02009;13</bold>
</th><th/></tr><tr valign="top"><th>
<bold>Mean (SD),</bold>
</th><th>
<bold>Mean (SD),</bold>
</th><th/><th>
<bold>Mean (SD),</bold>
</th><th>
<bold>Mean (SD),</bold>
</th><th/></tr><tr valign="top"><th>
<bold>Median (IQR)</bold>
</th><th>
<bold>Median (IQR)</bold>
</th><th/><th>
<bold>Median (IQR)</bold>
</th><th>
<bold>Median (IQR)</bold>
</th><th/></tr></thead><tbody><tr valign="top"><td colspan="2">
<bold>Endothelial function</bold>
</td><td/><td/><td/><td/><td/></tr><tr valign="top"><td>vWF (% Control)</td><td>141 (61)</td><td>139 (60)</td><td>0.92</td><td>158 (78)</td><td>169 (65)</td><td>0.68</td></tr><tr valign="top"><td>EDV (%)</td><td>3.5 (1.8, 5.3)</td><td>3.0 (1.5, 5.5)</td><td>0.42</td><td>6.0 (2.5, 8.5)</td><td>4.0 (2.0, 6.0)</td><td>0.32</td></tr><tr valign="top"><td>Vd/Vt</td><td>0.56 (0.06)</td><td>0.54 (0.05)</td><td>0.53</td><td>0.56 (0.06)</td><td>0.54 (0.06)</td><td>0.74</td></tr><tr valign="top"><td colspan="4">
<bold>Systemic and pulmonary inflammatory mediators</bold>
</td><td/><td/><td/></tr><tr valign="top"><td>Serum hsCRP (mgL<sup>&#x02212;1</sup>)</td><td>2.14 (0.97, 5.75)</td><td>1.83 (1.15, 4.49)</td><td>0.95</td><td>2.85 (1.45, 4.63)</td><td>1.96 (1.13, 4.23)</td><td>0.27</td></tr><tr valign="top"><td>Arterial pH</td><td>7.38 (0.04)</td><td>7.40 (0.05)</td><td>0.43</td><td>7.32 (0.08)</td><td>7.29 (0.06)</td><td>0.20</td></tr><tr valign="top"><td colspan="2">
<bold>Pulmonary function</bold>
</td><td/><td/><td/><td/><td/></tr><tr valign="top"><td>PaO<sub>2</sub>:FiO<sub>2</sub> ratio (kPa)</td><td>59.6 (47.8, 81.1)</td><td>59.6 (46.5, 97.7)</td><td>0.44</td><td>45.3 (28.3, 49.4)</td><td>42.5 (32.7, 51.4)</td><td>0.79</td></tr></tbody></table><table-wrap-foot><p>SD, Standard Deviation, IQR, Interquartile Range, EDV, Endothelium-dependent vasodilatation, vWF, von Willebrand Factor, Vd/Vt, Pulmonary Deadspace Fraction, EBC, Exhaled Breath Condensate, CRP, C Reactive Protein.</p></table-wrap-foot></table-wrap><fig id="Fig3"><label>Figure 3</label><caption><p>There was a significant increase in urinary ACR in the placebo group from 0.99(0.58,3.9) to 15.6(6.0,30.9)mg/mmol and in the treatment group from 0.77(0.5,2.6) to 8.1(3.1,26.3)mg/mmol. There were no differences between groups either pre- (p&#x02009;=&#x02009;0.56) or postoperatively (p&#x02009;=&#x02009;0.37).</p></caption><graphic xlink:href="40635_2015_50_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec9"><title>Effects of ascorbic acid on soluble adhesion molecules</title><p>Plasma sICAM-1 fell within both the placebo (p&#x02009;&#x0003c;&#x02009;0.001) and ascorbic acid (p&#x02009;=&#x02009;0.005) groups after open AAA repair, There was no difference between placebo and ascorbic acid groups pre-operatively (p&#x02009;=&#x02009;0.1) however plasma sICAM-1 was higher in the ascorbic acid group post-operatively (p&#x02009;=&#x02009;0.03 vs placebo, Figure <xref rid="Fig4" ref-type="fig">4</xref>A). Plasma sVCAM-1 was similar pre and post open AAA repair in both groups and there was no difference between groups (Figure <xref rid="Fig4" ref-type="fig">4</xref>B). Plasma sE-Selectin fell post-operatively within both the placebo (p&#x02009;&#x0003c;&#x02009;0.001) and ascorbic acid (p&#x02009;=&#x02009;0.002) groups, although there was no difference between the groups (Figure <xref rid="Fig4" ref-type="fig">4</xref>C). Plasma sP-Selectin fell post-operatively within the placebo (p&#x02009;=&#x02009;0.0001) but not the ascorbic acid (p&#x02009;=&#x02009;0.41) groups, although there was no difference between the groups (Figure <xref rid="Fig4" ref-type="fig">4</xref>D).<fig id="Fig4"><label>Figure 4</label><caption><p>Endothelial adhesion molecules. (<bold>A</bold>) Plasma sICAM-1 levels decreased in the placebo group from 245(50) to 162(51) ng/ml and in the ascorbic acid group from 287(79) to 204(52) ng/ml after AAA repair and post-operatively were significantly lower in the placebo group compared to ascorbic acid (p&#x02009;=&#x02009;0.03). (<bold>B</bold>) Plasma sVCAM-1 levels did not change after AAA repair. In the placebo group the preoperative level was 1132(427) ng/ml and post-operatively 998(484)ng/ml (p&#x02009;=&#x02009;0.3). In the ascorbic acid group the preoperative level was 1223(471)ng/ml and postoperatively 1088(505)ng/ml (p&#x02009;=&#x02009;0.4). There were no differences between groups and any time point. (<bold>C</bold>) sE-Selectin levels decreased in the placebo group from 35(12) to 25(13)ng/ml (p&#x02009;&#x0003c;&#x02009;0.001) and in the ascorbic acid group from 37(11) to 26(8)ng/ml (p&#x02009;=&#x02009;0.002) after AAA repair. There were no differences between groups. (<bold>D</bold>) sP-Selectin levels decreased in the placebo group from 82(52,88) to 59(52,75)ng/ml (p&#x02009;=&#x02009;0.001) after AAA repair. In the ascorbic acid group the levels were similar pre- and post-operatively (79(70,95) vs. 69(59,82)ng/ml) (p&#x02009;=&#x02009;0.4).</p></caption><graphic xlink:href="40635_2015_50_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec10"><title>Effects of ascorbic acid on systemic and pulmonary markers of inflammation</title><p>Plasma CRP was similar pre and post open AAA repair in both groups and there was no difference between groups (Table <xref rid="Tab2" ref-type="table">2</xref>). Plasma IL-6 increased during the study period in the placebo (p&#x02009;&#x0003c;&#x02009;0.001) and ascorbic acid (p&#x02009;&#x0003c;&#x02009;0.001) groups although there was no difference between the groups (Figure <xref rid="Fig5" ref-type="fig">5</xref>A). Similarly plasma IL-8 also increased significantly in both placebo (p&#x02009;&#x0003c;&#x02009;0.001) and ascorbic acid (p&#x02009;&#x0003c;&#x02009;0.001) groups but again there was no difference between the groups (Figure <xref rid="Fig5" ref-type="fig">5</xref>B).<fig id="Fig5"><label>Figure 5</label><caption><p>(<bold>A</bold>) IL-6 increased in the placebo group from 4.9(4.9,5.0) to 41.8(33.5,77.4) pg/ml (p&#x02009;&#x0003c;&#x02009;0.001) and in the ascorbic acid group from 4.9(4.9,5.0) to 29.0(13.3,52.3) pg/ml (p&#x02009;&#x0003c;&#x02009;0.001) after AAA repair. (<bold>B</bold>) IL-8 levels increased in the placebo group from 9.5(5.6,15.6) to 33.6(18.3,38.6) pg/ml (p&#x02009;&#x0003c;&#x02009;0.001) and in the ascorbic acid group from 9.8(3.7,13.7) to 20.7(14.8,52.9) pg/ml (p&#x02009;&#x0003c;&#x02009;0.001) after open AAA repair. There was no difference between groups at any time-point for either of these inflammatory mediators.</p></caption><graphic xlink:href="40635_2015_50_Fig5_HTML" id="MO5"/></fig></p><p>EBC pH decreased in both the placebo (p&#x02009;=&#x02009;0.008) and ascorbic acid (p&#x02009;=&#x02009;0.002) groups post-operatively although there was no difference between the groups (Figure <xref rid="Fig6" ref-type="fig">6</xref>). Systemic arterial pH also decreased in both the placebo (p&#x02009;&#x0003c;&#x02009;0.001) and ascorbic acid (p&#x02009;=&#x02009;0.005) groups post-operatively although there was no difference between the groups (Table <xref rid="Tab2" ref-type="table">2</xref>). There was no significant correlation in the change in systemic arterial pH and EBC pH in either the placebo (p&#x02009;=&#x02009;0.52, r<sup>2</sup>&#x02009;=&#x02009;0.03) or ascorbic acid (p&#x02009;=&#x02009;0.23, r<sup>2</sup>&#x02009;=&#x02009;0.13) groups.<fig id="Fig6"><label>Figure 6</label><caption><p>EBC pH decreased in the placebo group from 7.38(0.04) to 7.32(0.08) (p&#x02009;=&#x02009;0.008) after open AAA repair. In the ascorbic acid group the EBC pH fell from 7.40(0.05) to 7.29(0.06) (p&#x02009;=&#x02009;0.002) post-operatively. The pre- and post-operative levels were similar between groups (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p></caption><graphic xlink:href="40635_2015_50_Fig6_HTML" id="MO6"/></fig></p></sec><sec id="Sec11"><title>Effects of ascorbic acid on systemic oxidative stress</title><p>Plasma lipid hydroperoxides decreased in the placebo group (p&#x02009;=&#x02009;0.002) but not in the ascorbic acid group (p&#x02009;=&#x02009;0.38). Furthermore post-operative lipid hydroperoxides were significantly higher in the ascorbic acid group (p&#x02009;&#x0003c;&#x02009;0.001, Figure <xref rid="Fig7" ref-type="fig">7</xref>A). Plasma 8-isoprostane was similar pre and post open AAA repair in both groups and there was no difference between groups (Figure <xref rid="Fig7" ref-type="fig">7</xref>B).<fig id="Fig7"><label>Figure 7</label><caption><p>Oxidative stress markers. (<bold>A</bold>) Lipid hydroperoxide decreased in the placebo group from 0.8(0.7,0.9) to 0.5(0.4,0.5)&#x003bc;mol/l (p&#x02009;=&#x02009;0.002) after AAA repair. In the ascorbic acid group the preoperative level 0.6(0.5,0.7)&#x003bc;mol/l did not change and postoperatively was 0.6(0.6,0.8)&#x003bc;mol/l (p&#x02009;=&#x02009;0.4). Post-operatively lipid hydroperoxide levels were significantly higher in the ascorbic acid group compared with placebo (p&#x02009;&#x0003c;&#x02009;0.001). (<bold>B</bold>) Plasma 8-isoprostane levels did not change after AAA repair in either group and there was no difference between groups at any time-point. In the placebo group the preoperative level 18.4(15.9,24.8)ng/ml did not change after AAA repair being 20.4(18.6,25.1)ng/ml (p&#x02009;=&#x02009;0.3). In the ascorbic acid group the preoperative level 19.1(16.6,23.7)ng/ml did not change and postoperatively was 19.7(18.2,23.2)ng/ml (p&#x02009;=&#x02009;0.6). There was no difference between groups at any time point.</p></caption><graphic xlink:href="40635_2015_50_Fig7_HTML" id="MO7"/></fig></p></sec><sec id="Sec12"><title>Effects of ascorbic acid on pulmonary function and clinical outcomes</title><p>The PaO<sub>2</sub>:FiO<sub>2</sub> ratio fell significantly in both placebo (p&#x02009;=&#x02009;0.002) and ascorbic acid (p&#x02009;&#x0003c;&#x02009;0.001) groups although there was no difference between groups (Figure <xref rid="Fig8" ref-type="fig">8</xref>).<fig id="Fig8"><label>Figure 8</label><caption><p>The PaO2:FiO2 ratio decreased in the placebo group from 447 (398, 608) to 340 (212, 370) mmHg (p&#x02009;=&#x02009;0.002) and in the ascorbic acid group from 447 (349, 733) to 319 (245, 385) mmHg (p&#x02009;=&#x02009;0.002) after AAA repair. There were no differences demonstrated between groups (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p></caption><graphic xlink:href="40635_2015_50_Fig8_HTML" id="MO8"/></fig></p><p>Post-operative infections were diagnosed in 3 (17%) of the placebo group and in 2 (8%) of the ascorbate group (p&#x02009;=&#x02009;0.62). Only 3 patients in each group required post-operative invasive ventilation and the duration of ventilation was similar between groups (p&#x02009;=&#x02009;0.77). The duration of stay in critical care was similar between the placebo and ascorbic acid groups (2.9 (3.5) days versus 2.3 (3.2) days, p&#x02009;=&#x02009;0.64). Similarly there was no difference in hospital stay (10.2 (4.8) versus 8.8 (2.6) days, p&#x02009;=&#x02009;0.37). There was one post-operative fatality in the placebo group. No serious adverse reactions related to the study drug occurred.</p></sec></sec><sec id="Sec13" sec-type="discussion"><title>Discussion</title><p>We have found that open AAA repair caused significant changes in markers of systemic endothelial dysfunction as well as an increase in systemic and pulmonary inflammation, and a reduction in a marker of pulmonary function. However ascorbic acid therapy did not attenuate changes in these biomarkers following open AAA repair.</p><p>Our findings are in keeping with previous data showing increased urinary ACR and inflammation and with a decrease in PaO<sub>2</sub>:FiO<sub>2</sub> ratio following open AAA repair [<xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR38">38</xref>]. In contrast to these findings however we did not see an increased serum CRP or increased plasma vWF. An increasing proportion of participants now receive treatment for co-morbid conditions such as statins. Statins have anti-inflammatory effects [<xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR39">39</xref>] and may modulate endothelial function modifying responses to open AAA surgery. We found no increase in pulmonary dead space fraction. It is possible that the injury was not sufficient to induce pulmonary endothelial dysfunction or that the time to post operative assessment was of insufficient duration. As part of the standardized anaesthetic protocol, maintenance was with sevoflurane which has been shown to protect the endothelium from ischaemia-reperfusion injury [<xref ref-type="bibr" rid="CR40">40</xref>] and might have further attenuated any potential pulmonary endothelial injury.</p><p>The fall in EBC pH as a marker of alveolar neutrophilic inflammation was an interesting finding. This was associated with a decrease in the PaO<sub>2</sub>:FiO<sub>2</sub> ratio. The fall in EBC pH in this study may reflect pulmonary inflammation given that there was no correlation found with this decrease and changes in systemic pH.</p><p>Ischaemia-reperfusion injury has been used to provoke acute lung injury (ALI) in animal models [<xref ref-type="bibr" rid="CR41">41</xref>]. The obligate ischaemia-reperfusion injury of open AAA repair is associated with post operative pulmonary dysfunction [<xref ref-type="bibr" rid="CR42">42</xref>]. A recent observational study found that post-operative respiratory failure was associated with increased mortality [<xref ref-type="bibr" rid="CR43">43</xref>]. Reflecting findings in ALI, we have shown open AAA repair is associated with local alveolar inflammation as well as systemic endothelial dysfunction and inflammation. Elevated plasma IL-6 and -8 levels are predictive of outcome in patients with ALI [<xref ref-type="bibr" rid="CR44">44</xref>]. As a marker of systemic vascular permeability, urinary ACR has been shown to have an inverse relationship with PaO<sub>2</sub>:FiO<sub>2</sub> ratio in a cohort of trauma patients [<xref ref-type="bibr" rid="CR45">45</xref>]. These findings support the use of open AAA repair as a human model of ALI induced by systemic inflammation. However, in the present study mediators implicated in ALI such as vWF [<xref ref-type="bibr" rid="CR11">11</xref>] were not elevated. It is possible that endothelial injury was not caused to a measurable level. In a murine model of ALI the administration of parenteral ascorbic acid (200 mg/ml) 30 minutes after a septic insult attenuated the inflammatory response and was associated with improved survival, pulmonary function and coagulation [<xref ref-type="bibr" rid="CR21">21</xref>]. In this study Fisher and colleagues suggested that the protective effects of ascorbic acid are due to its pleotropic actions on multiple pathways and it is possible in the current study, a lack of benefit may be related to the limitations in biomarkers used.</p><p>We investigated a single 2 g bolus of intravenous ascorbic acid following induction of anaesthesia in this study. This dose was informed by previous research where pre-treatment with 2 g ascorbic acid was found to modulate the adverse haemodynamic effects of experimentally induced hyperglycaemia [<xref ref-type="bibr" rid="CR46">46</xref>]. In addition ascorbic acid (2 g) has been shown to prevent hyperglycaemia-induced endothelial dysfunction in healthy human volunteers [<xref ref-type="bibr" rid="CR47">47</xref>].</p><p>In the present study a decrease in plasma adhesion molecules was found. Haemodilution as part of intra-operative management could be potential mechanism for the reduction in soluble adhesion molecules as well as the lack of increase in serum hsCRP. However, as plasma IL-6 and IL-8 both increased, haemodilution is less likely. Co-morbid treatment may also have influenced adhesion molecules expression. Both statins and &#x003b2; blockers may modify adhesion molecules expression. Human coronary endothelial cells treated with nebivolol in vitro have a decrease in VCAM-1, ICAM-1, E- and P-Selectin expression [<xref ref-type="bibr" rid="CR48">48</xref>]. Interestingly in another study of open AAA repair there was a non-significant fall in both ICAM-1 and VCAM-1 [<xref ref-type="bibr" rid="CR49">49</xref>]. This has been mirrored in an in vitro study of human aortic endothelial cells which showed exposure of these cells to hypoxia and subsequent reoxygenation did not upregulate surface expression or shedding of adhesion molecules [<xref ref-type="bibr" rid="CR50">50</xref>].</p><p>There was no increase in markers of oxidative stress in the placebo group unlike in other studies. Prosaglandin F<sub>2&#x003b1;</sub> is increased both on hospital arrival and during the perioperative period in patients with ruptured AAA repair [<xref ref-type="bibr" rid="CR51">51</xref>]. Malondialdehyde, another marker of oxidative damage was increased at one and 24 hours post open AAA repair [<xref ref-type="bibr" rid="CR52">52</xref>]. In a recent small observational study derivatives of reactive oxygen metabolites were used to define post-operative oxidative stress in patients undergoing aortic surgery. This showed that in those having open AAA repair this marker was no different at 24 hours after surgery, but was significantly elevated 1 week later [<xref ref-type="bibr" rid="CR53">53</xref>]. This study had an earlier sampling time, older cohort of patients and aortic clamp times contributing to the different data between studies.</p><p>Ascorbic acid did not improve markers of endothelial function or attenuate the inflammatory response markers in this study. In previous research pretreatment with 2000mg parenteral ascorbic acid prevented arterial stiffness secondary to induced hyperglycaemia in healthy male volunteers [<xref ref-type="bibr" rid="CR23">23</xref>]. In a study of 37 critically ill patients with burns the use of high dose ascorbic acid (66 mg/kg/hr) for 24 hours reduced fluid requirements, wound oedema, and severity of pulmonary dysfunction [<xref ref-type="bibr" rid="CR25">25</xref>]. In a double-blind randomized placebo-controlled trial of 216 critically ill patients, enteral ascorbic acid (500 mg/day) and tocopherol (400 IU/day) was associated with a decrease in 8-isoprostane. The anti-oxidant treated group had improved 28-day mortality and more ventilator free days [<xref ref-type="bibr" rid="CR54">54</xref>]. We found lipid hydroperoxides were increased with ascorbic acid. This increase in lipid peroxides was not seen in plasma 8-isoprostanes, another measure of oxidative stress. Lipid hydroperoxides can be affected by dietary factors not accounted for in the current study. Isoprostane levels however, are not affected by diet [<xref ref-type="bibr" rid="CR55">55</xref>] and may be a better measure of oxidative stress [<xref ref-type="bibr" rid="CR56">56</xref>]. Previous studies utilizing the FOX assay have indicated its lack of specificity for hydroperoxides [<xref ref-type="bibr" rid="CR57">57</xref>]. However, in keeping with our findings, Bailey at al found 2000 mg ascorbic acid orally two hours before operation in patients undergoing major vascular surgery increased both lipid peroxides and plasma IL-6 [<xref ref-type="bibr" rid="CR58">58</xref>]. Possible reasons for increased oxidative stress markers in this current study may relate to the timing of sampling and range of ischaemic times. It is possible that at the dose used in this study, ascorbic acid acted as a pro-oxidant with no beneficial effects on either the endothelium or measured mediators of inflammation.</p><p>There are numerous limitations in this study. The patient cohort was small increasing the risk of a type 2 error. Within the participants neither aneurysm size or anatomical location were described. Duration of aortic clamping was recorded but the position was not noted. Although the surgical approach and anaesthetic technique was standardized the quantities of transfused blood products and fluids were not compared. Similarly the need for cardiovascular support was not quantified. These confounding factors may have had a consequence on the resultant endothelial injury. Having taken measurements using a limited number of biomarkers of organ dysfunction up to only 4 hours following aortic clamping may increase the risk of a type 1 error.</p></sec><sec id="Sec14" sec-type="conclusions"><title>Conclusion</title><p>In conclusion, open AAA repair caused increased markers of systemic endothelial dysfunction and inflammation with an associated fall in oxygenation. These findings support the use of open AAA repair as a human model of ALI induced by systemic inflammation. Ascorbic acid administration did not improve the measured biomarkers and limited functional parameters observed.</p></sec></body><back><fn-group><fn><p><bold>Competing interests</bold></p><p>MJD has received payments from Otsuka Pharmaceuticals for lectures. MS has financial interest in AstraZeneca DFM DWH, BAM no interests to declare. DFM and CMO&#x02019;K have received consultancy fees from Orion, GlaxoSmithKline and AstraZeneca and have research funding from GlaxoSmithKline for Acute Lung Injury. ISY has received funding for lectures from Astra Zeneca, Merck and Roche and is a member of the advisory committee on nutrition to Dept of Health UK.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>MJD, BAM, CMO&#x02019;K, DFM, DWH: Study design and conduct. MJD, ISY: Laboratory analyses. MJD, BAM, DFM: Manuscript authors. MJD, MS: Data analyses. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We wish to acknowledge those patients and their families who agreed to participate in the study.</p><sec id="FPar1"><title>Funding</title><p>This study was funded by a research grant from the British Journal of Anaesthesia / RCoA. Equipment was provided by a grant from the Vascular Anaesthetic Society of Great Britain and Ireland. The research team also received a small grant from Revive, the Regional Intensive Care Unit Charity.</p></sec><sec id="FPar2"><title>Attribution of Work</title><p>Centre for Infection and Immunity, The Queen's University Belfast</p><p>Regional Intensive Care Unit, Royal Victoria Hospital, Belfast</p></sec><sec id="FPar3"><title>Summary statement</title><p>A prospective randomized controlled trial of ascorbic acid in open AAA repair demonstrated pulmonary and systemic endothelial injury with increased systemic inflammation postoperatively. The administration of ascorbic acid did not attenuate biomarkers of endothelial damage.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bown</surname><given-names>M</given-names></name><name><surname>Nicholson</surname><given-names>ML</given-names></name><name><surname>Bell</surname><given-names>PRF</given-names></name><name><surname>Sayers</surname><given-names>RD</given-names></name></person-group><article-title>Cytokines and inflammatory pathways in the pathogenesis of multiple organ failure following abdominal aortic aneurysm repair</article-title><source>Eur J Vasc Endovasc Surg</source><year>2001</year><volume>22</volume><fpage>485</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1053/ejvs.2001.1522</pub-id><pub-id pub-id-type="pmid">11735196</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCord</surname><given-names>J</given-names></name></person-group><article-title>Oxygen-derived free radicals in postischemic tissue injury</article-title><source>N Engl J Med</source><year>1985</year><volume>312</volume><fpage>159</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1056/NEJM198501173120305</pub-id><pub-id pub-id-type="pmid">2981404</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edrees</surname><given-names>WK</given-names></name><name><surname>Lau</surname><given-names>LL</given-names></name><name><surname>Young</surname><given-names>IS</given-names></name><name><surname>Smye</surname><given-names>MG</given-names></name><name><surname>Gardiner</surname><given-names>KR</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Hannon</surname><given-names>RJ</given-names></name><name><surname>Soong</surname><given-names>CV</given-names></name></person-group><article-title>The effect of lower limb ischaemia-reperfusion on intestinal permeability and the systemic inflammatory response</article-title><source>Eur J Vasc Endovasc Surg</source><year>2003</year><volume>25</volume><fpage>330</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1053/ejvs.2002.1848</pub-id><pub-id pub-id-type="pmid">12651171</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrow</surname><given-names>J</given-names></name><name><surname>Roberts</surname><given-names>L</given-names></name></person-group><article-title>The isoprostanes their role as an index of oxidant stress status in human pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>2002</year><volume>166</volume><fpage>S25</fpage><lpage>S30</lpage><pub-id pub-id-type="doi">10.1164/rccm.2206011</pub-id><pub-id pub-id-type="pmid">12471085</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Entman</surname><given-names>M</given-names></name><name><surname>Youker</surname><given-names>K</given-names></name><name><surname>Shappell</surname><given-names>S</given-names></name></person-group><article-title>Neutrophil adherence to isolated adult canine myocytes. Evidence for a CD18-dependent mechanism</article-title><source>J Clin Invest</source><year>1990</year><volume>85</volume><fpage>1497</fpage><lpage>1506</lpage><pub-id pub-id-type="doi">10.1172/JCI114596</pub-id><pub-id pub-id-type="pmid">1970581</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shreeniwas</surname><given-names>R</given-names></name><name><surname>Koga</surname><given-names>S</given-names></name><name><surname>Karakurum</surname><given-names>M</given-names></name></person-group><article-title>Hypoxia mediated induction of endothelial cell interleukin-1 alpha</article-title><source>An autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface. J Clin Invest</source><year>1992</year><volume>90</volume><fpage>2333</fpage><lpage>2339</lpage></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karakurum</surname><given-names>M</given-names></name><name><surname>Shreeniwas</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Pinsky</surname><given-names>D</given-names></name><name><surname>Yan</surname><given-names>SD</given-names></name><name><surname>Anderson</surname><given-names>M</given-names></name><name><surname>Sunouchi</surname><given-names>K</given-names></name><name><surname>Major</surname><given-names>J</given-names></name><name><surname>Hamilton</surname><given-names>T</given-names></name><name><surname>Kuwabara</surname><given-names>K</given-names></name><name><surname>Rot</surname><given-names>A</given-names></name><name><surname>Nowygrod</surname><given-names>R</given-names></name><name><surname>Stern</surname><given-names>D</given-names></name></person-group><article-title>Hypoxic Induction of Interleukin-8 Gene Expression in Human Endothelial Cells</article-title><source>J Clin Invest</source><year>1994</year><volume>93</volume><fpage>1564</fpage><lpage>1570</lpage><pub-id pub-id-type="doi">10.1172/JCI117135</pub-id><pub-id pub-id-type="pmid">8163658</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malik</surname><given-names>A</given-names></name><name><surname>Sultan</surname><given-names>S</given-names></name><name><surname>Turner</surname><given-names>S</given-names></name></person-group><article-title>Urinary albumin excretion is associated with impaired flow- and nitroglycerin- mediated brachial artery dilatation in hypertensive adults</article-title><source>J Hum Hypertens</source><year>2007</year><volume>21</volume><fpage>231</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17230233</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedrinelli</surname><given-names>R</given-names></name><name><surname>Dell&#x02019;Omo</surname><given-names>G</given-names></name><name><surname>Penno</surname><given-names>G</given-names></name></person-group><article-title>Non-diabetic microalbuminuria, endothelial dysfunction and cardiovascular disease</article-title><source>Vasc Med</source><year>2001</year><volume>6</volume><fpage>257</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1177/1358836X0100600410</pub-id><pub-id pub-id-type="pmid">11958393</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norwood</surname><given-names>M</given-names></name><name><surname>Sayers</surname><given-names>R</given-names></name></person-group><article-title>Urinary Albumin:Creatinine Ratio (ACR) and the Prediction of Postoperative Complications After Abdominal Aortic Aneurysm Repair</article-title><source>Eur J Vasc Endovasc Surg</source><year>2005</year><volume>30</volume><fpage>353</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1016/j.ejvs.2005.04.042</pub-id><pub-id pub-id-type="pmid">15939638</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>LB</given-names></name><name><surname>Eisner</surname><given-names>MD</given-names></name><name><surname>Thompson</surname><given-names>BT</given-names></name><name><surname>Parsons</surname><given-names>PE</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name></person-group><article-title>Significance of von willebrand factor in septic and non-septic patients with acute lung injury</article-title><source>Am J Resp Crit Care Med</source><year>2004</year><volume>170</volume><issue>7</issue><fpage>766</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1164/rccm.200310-1434OC</pub-id><pub-id pub-id-type="pmid">15201135</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rittoo</surname><given-names>D</given-names></name></person-group><article-title>Randomized study comparing the effects of hydroxyethyl starch solution with gelofusine on activated endothelium and the systemic AAinflammatory response following aortic aneurysm repair</article-title><source>Eur J Vasc Endovasc Surg</source><year>2005</year><volume>30</volume><issue>5</issue><fpage>520</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1016/j.ejvs.2005.04.046</pub-id><pub-id pub-id-type="pmid">15963746</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>FC</given-names></name><name><surname>Gosling</surname><given-names>P</given-names></name><name><surname>Sanghera</surname><given-names>K</given-names></name><name><surname>Green</surname><given-names>MA</given-names></name><name><surname>Paterson</surname><given-names>IS</given-names></name><name><surname>Shearman</surname><given-names>CP</given-names></name></person-group><article-title>Microproteinuria predicts the severity of systemic effects of reperfusion injury following infrarenal aortic aneurysm surgery</article-title><source>Ann Vasc Surg</source><year>1994</year><volume>8</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1007/BF02133398</pub-id><pub-id pub-id-type="pmid">8192991</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duffy</surname><given-names>MJ</given-names></name><name><surname>Mullan</surname><given-names>BA</given-names></name><name><surname>Craig</surname><given-names>TR</given-names></name><name><surname>Shyamsundar</surname><given-names>M</given-names></name><name><surname>MacSweeney</surname><given-names>RE</given-names></name><name><surname>Thompson</surname><given-names>G</given-names></name><name><surname>Stevenson</surname><given-names>M</given-names></name><name><surname>McAuley</surname><given-names>DF</given-names></name></person-group><article-title>Impaired endothelium-dependent vasodilatation is a novel predictor of mortality in intensive care</article-title><source>Crit Care Med</source><year>2011</year><volume>39</volume><issue>4</issue><fpage>629</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e318206bc4a</pub-id><pub-id pub-id-type="pmid">21242802</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nuckton</surname><given-names>TJ</given-names></name><name><surname>Alonso</surname><given-names>JA</given-names></name><name><surname>Kallet</surname><given-names>RH</given-names></name><name><surname>Daniel</surname><given-names>BM</given-names></name><name><surname>Pittet</surname><given-names>JF</given-names></name><name><surname>Eisner</surname><given-names>MD</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name></person-group><article-title>Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome</article-title><source>N Engl J Med</source><year>2002</year><volume>346</volume><fpage>1281</fpage><lpage>1286</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa012835</pub-id><pub-id pub-id-type="pmid">11973365</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>J</given-names></name></person-group><article-title>Mechanism of action of vitamin C in sepsis: Ascorbate modulates redox signaling in endothelium</article-title><source>Biofactors</source><year>2009</year><volume>35</volume><issue>1</issue><fpage>5</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1002/biof.7</pub-id><pub-id pub-id-type="pmid">19319840</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frei</surname><given-names>B</given-names></name><name><surname>England</surname><given-names>L</given-names></name><name><surname>Ames</surname><given-names>B</given-names></name></person-group><article-title>Ascorbate is an outstanding antioxidant in human blood plasma</article-title><source>Proc Natl Acad Sci U S A</source><year>1989</year><volume>86</volume><fpage>6377</fpage><lpage>6381</lpage><pub-id pub-id-type="doi">10.1073/pnas.86.16.6377</pub-id><pub-id pub-id-type="pmid">2762330</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietri</surname><given-names>S</given-names></name><name><surname>Seguin</surname><given-names>JR</given-names></name><name><surname>d&#x02019;Arbigny</surname><given-names>P</given-names></name><name><surname>Culcasi</surname><given-names>M</given-names></name></person-group><article-title>Ascorbyl free radical: a noninvasive marker of oxidative stress in human open-heart surgery</article-title><source>Free Radic Biol Med</source><year>1994</year><volume>16</volume><fpage>523</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1016/0891-5849(94)90131-7</pub-id><pub-id pub-id-type="pmid">8005538</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lassnigg</surname><given-names>A</given-names></name><name><surname>Punz</surname><given-names>A</given-names></name><name><surname>Barker</surname><given-names>R</given-names></name><name><surname>Keznicki</surname><given-names>P</given-names></name><name><surname>Manhart</surname><given-names>N</given-names></name><name><surname>Roth</surname><given-names>E</given-names></name><name><surname>Hiesmayr</surname><given-names>M</given-names></name></person-group><article-title>Influence of intravenous vitamin E supplementation in cardiac surgery on oxidative stress: a double-blinded, randomized, controlled study</article-title><source>Br J Anaesth</source><year>2003</year><volume>90</volume><fpage>148</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1093/bja/aeg042</pub-id><pub-id pub-id-type="pmid">12538369</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fain</surname><given-names>O</given-names></name><name><surname>Paries</surname><given-names>J</given-names></name><name><surname>Jacquart</surname><given-names>B</given-names></name><name><surname>LeMoel</surname><given-names>G</given-names></name><name><surname>Kettaneh</surname><given-names>A</given-names></name><name><surname>Stirnemann</surname><given-names>J</given-names></name><name><surname>Heron</surname><given-names>C</given-names></name><name><surname>Stibon</surname><given-names>M</given-names></name><name><surname>Taleb</surname><given-names>C</given-names></name><name><surname>Letellier</surname><given-names>E</given-names></name><name><surname>Betari</surname><given-names>B</given-names></name><name><surname>Gattegno</surname><given-names>L</given-names></name><name><surname>Thomas</surname><given-names>M</given-names></name></person-group><article-title>Hypovitaminosis C in hospitalized patients</article-title><source>Eur J Intern Med</source><year>2003</year><volume>14</volume><fpage>419</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1016/j.ejim.2003.08.006</pub-id><pub-id pub-id-type="pmid">14614974</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>BJ</given-names></name><name><surname>Krausauskas</surname><given-names>D</given-names></name><name><surname>Martin</surname><given-names>EJ</given-names></name><name><surname>Farkas</surname><given-names>D</given-names></name><name><surname>Wegelin</surname><given-names>JA</given-names></name><name><surname>Brophy</surname><given-names>D</given-names></name><name><surname>Ward</surname><given-names>KR</given-names></name><name><surname>Voelkel</surname><given-names>NF</given-names></name><name><surname>Fowler</surname><given-names>AA</given-names><suffix>III</suffix></name><name><surname>Natarajan</surname><given-names>R</given-names></name></person-group><article-title>Mechanisms of attenuation of abdominal sepsis induced acute lung injury by ascorbic acid</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2012</year><volume>303</volume><fpage>L20</fpage><lpage>L32</lpage><pub-id pub-id-type="doi">10.1152/ajplung.00300.2011</pub-id><pub-id pub-id-type="pmid">22523283</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>L</given-names></name><name><surname>Matthay</surname><given-names>M</given-names></name></person-group><article-title>The acute respiratory distress syndrome</article-title><source>New Eng J Med</source><year>2000</year><volume>342</volume><issue>18</issue><fpage>1334</fpage><lpage>1349</lpage><pub-id pub-id-type="doi">10.1056/NEJM200005043421806</pub-id><pub-id pub-id-type="pmid">10793167</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullan</surname><given-names>BA</given-names></name><name><surname>Ennis</surname><given-names>CN</given-names></name><name><surname>Fee</surname><given-names>HJ</given-names></name><name><surname>Young</surname><given-names>IS</given-names></name><name><surname>McCance</surname><given-names>DR</given-names></name></person-group><article-title>Protective effects of ascorbic acid on arterial haemodynamics during acute hyperglycaemia</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2004</year><volume>287</volume><fpage>H1262</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00153.2003</pub-id><pub-id pub-id-type="pmid">15087291</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>J</given-names></name></person-group><article-title>Sepsis: rethinking the approach to clinical research</article-title><source>J Leukoc Biol</source><year>2008</year><volume>83</volume><fpage>471</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1189/jlb.0607380</pub-id><pub-id pub-id-type="pmid">18171697</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Matsuda</surname><given-names>T</given-names></name><name><surname>Miyagantani</surname><given-names>Y</given-names></name><name><surname>Yukioka</surname><given-names>T</given-names></name><name><surname>Maysuda</surname><given-names>H</given-names></name><name><surname>Shimazaki</surname><given-names>S</given-names></name></person-group><article-title>Reduction of resuscitation fluid volumes in severely burned patients using ascorbic acid administration: a randomized, prospective study</article-title><source>Arch Surg</source><year>2000</year><volume>135</volume><fpage>326</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1001/archsurg.135.3.326</pub-id><pub-id pub-id-type="pmid">10722036</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Tyml</surname><given-names>K</given-names></name><name><surname>Wilson</surname><given-names>J</given-names></name></person-group><article-title>iNOS expression requires NADPH oxidase-dependent redox signaling in microvascular endothelial cells</article-title><source>J Cell Physiol</source><year>2008</year><volume>217</volume><fpage>207</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1002/jcp.21495</pub-id><pub-id pub-id-type="pmid">18481258</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landmesser</surname><given-names>U</given-names></name><name><surname>Dikalov</surname><given-names>S</given-names></name><name><surname>Price</surname><given-names>SR</given-names></name><name><surname>McCann</surname><given-names>L</given-names></name><name><surname>Fukai</surname><given-names>T</given-names></name><name><surname>Holland</surname><given-names>SM</given-names></name><name><surname>Mitch</surname><given-names>WE</given-names></name><name><surname>Harrison</surname><given-names>DG</given-names></name></person-group><article-title>Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension</article-title><source>J Clin Invest</source><year>2003</year><volume>111</volume><fpage>1201</fpage><lpage>1209</lpage><pub-id pub-id-type="doi">10.1172/JCI200314172</pub-id><pub-id pub-id-type="pmid">12697739</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shyamsundar</surname><given-names>M</given-names></name><name><surname>McKeown</surname><given-names>STW</given-names></name><name><surname>O&#x02019;Kane</surname><given-names>CM</given-names></name><name><surname>Craig</surname><given-names>TR</given-names></name><name><surname>Brown</surname><given-names>V</given-names></name><name><surname>Thickett</surname><given-names>DR</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name><name><surname>Taggart</surname><given-names>CC</given-names></name><name><surname>Backman</surname><given-names>JT</given-names></name><name><surname>Elborn</surname><given-names>JS</given-names></name><name><surname>McAuley</surname><given-names>DF</given-names></name></person-group><article-title>Simvastatin Decreases Lipopolysaccharide-induced Pulmonary Inflammation in Healthy Volunteers</article-title><source>Am J Respir Crit Care Med</source><year>2009</year><volume>179</volume><fpage>1107</fpage><lpage>1114</lpage><pub-id pub-id-type="doi">10.1164/rccm.200810-1584OC</pub-id><pub-id pub-id-type="pmid">19324974</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Hunt</surname><given-names>J</given-names></name><name><surname>Wolff</surname><given-names>S</given-names></name></person-group><article-title>Ferrous ion oxidation in the presence of xylenol orange for detection of lipid hydroperoxide in low density lipoprotein</article-title><source>Anal Biochem</source><year>1992</year><volume>202</volume><issue>2</issue><fpage>382</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1016/0003-2697(92)90122-N</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vuillemier</surname><given-names>J</given-names></name></person-group><article-title>Fluorometric assay of vitamin C in biological materials using a centrifugal analyser with fluorescence attachment</article-title><source>J Micronut Analysis</source><year>1989</year><volume>5</volume><fpage>25</fpage><lpage>34</lpage></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Junge</surname><given-names>W</given-names></name><name><surname>Wilke</surname><given-names>B</given-names></name><name><surname>Halabi</surname><given-names>A</given-names></name><name><surname>Klein</surname><given-names>G</given-names></name></person-group><article-title>Determination of reference intervals for serum creatinine, creatinine and creatinine clearance with an enzymatic and a modified Jaffe method</article-title><source>Clin Chim Acta</source><year>2004</year><volume>344</volume><fpage>137</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/j.cccn.2004.02.007</pub-id><pub-id pub-id-type="pmid">15149882</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkinson</surname><given-names>IB</given-names></name><name><surname>MacCallum</surname><given-names>H</given-names></name><name><surname>Cockcroft</surname><given-names>JR</given-names></name><name><surname>Webb</surname><given-names>DJ</given-names></name></person-group><article-title>Pulse wave analysis and arterial stiffness</article-title><source>J Cardiovasc Pharmacol</source><year>1998</year><volume>32</volume><issue>Suppl 3</issue><fpage>S33</fpage><lpage>S37</lpage><pub-id pub-id-type="pmid">9883745</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkinson</surname><given-names>IB</given-names></name><name><surname>Hall</surname><given-names>IR</given-names></name><name><surname>MacCallum</surname><given-names>H</given-names></name><name><surname>MacKenzie</surname><given-names>IS</given-names></name><name><surname>McEniery</surname><given-names>CM</given-names></name><name><surname>van der Arend</surname><given-names>BJ</given-names></name><name><surname>Shu</surname><given-names>Y</given-names></name><name><surname>MacKay</surname><given-names>LS</given-names></name><name><surname>Webb</surname><given-names>DJ</given-names></name><name><surname>Cockroft</surname><given-names>JR</given-names></name></person-group><article-title>Pulse-wave analysis:clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2002</year><volume>22</volume><fpage>147</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1161/hq0102.101770</pub-id><pub-id pub-id-type="pmid">11788475</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lind</surname><given-names>L</given-names></name><name><surname>Petterson</surname><given-names>K</given-names></name><name><surname>Johansson</surname><given-names>K</given-names></name></person-group><article-title>Analysis of endothelium dependent vasodilation by use of the radial artery pulse wave obtained by applanation tonometry</article-title><source>Clin Physiol Func Im</source><year>2003</year><volume>23</volume><fpage>50</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1046/j.1475-097X.2003.00469.x</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cepkova</surname><given-names>M</given-names></name><name><surname>Kapur</surname><given-names>V</given-names></name><name><surname>Ren</surname><given-names>X</given-names></name><name><surname>Quinn</surname><given-names>T</given-names></name><name><surname>Zhuo</surname><given-names>H</given-names></name><name><surname>Foster</surname><given-names>E</given-names></name><name><surname>Liu</surname><given-names>KD</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name></person-group><article-title>Pulmonary dead space fraction and pulmonary artery systolic pressure as early predictors of clinical outcome in acute lung injury</article-title><source>Chest</source><year>2007</year><volume>132</volume><fpage>836</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1378/chest.07-0409</pub-id><pub-id pub-id-type="pmid">17573490</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kallet</surname><given-names>RH</given-names></name><name><surname>Daniel</surname><given-names>BM</given-names></name><name><surname>Garcia</surname><given-names>O</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name></person-group><article-title>Accuracy of physiologic dead space measurements in patients with acute respiratory distress syndrome using volumetric capnography: comparison with the metabolic monitor method</article-title><source>Respir Care</source><year>2005</year><volume>50</volume><issue>4</issue><fpage>462</fpage><lpage>467</lpage><pub-id pub-id-type="pmid">15807908</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moloney</surname><given-names>ED</given-names></name><name><surname>Mumby</surname><given-names>SE</given-names></name><name><surname>Gajdocsi</surname><given-names>R</given-names></name><name><surname>Cranshaw</surname><given-names>JH</given-names></name><name><surname>Kharitonov</surname><given-names>SA</given-names></name><name><surname>Quinlan</surname><given-names>GJ</given-names></name><name><surname>Griffiths</surname><given-names>MJ</given-names></name></person-group><article-title>Exhaled breath condensate detects markers of pulmonary inflammation after cardiothoracic surgery</article-title><source>Am J Respir Crit Care Med</source><year>2004</year><volume>169</volume><fpage>64</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1164/rccm.200307-1005OC</pub-id><pub-id pub-id-type="pmid">14551168</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rittoo</surname><given-names>D</given-names></name><name><surname>Gosling</surname><given-names>P</given-names></name><name><surname>Burnley</surname><given-names>S</given-names></name></person-group><article-title>Randomized study comparing the effects of hydroxyethyl starch solution with gelofusine on pulmonary function in patients undergoing abdominal aortic aneurysm surgery</article-title><source>Br J Anaesth</source><year>2004</year><volume>92</volume><fpage>61</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1093/bja/aeh024</pub-id><pub-id pub-id-type="pmid">14665554</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Craig</surname><given-names>TR</given-names></name><name><surname>Duffy</surname><given-names>MJ</given-names></name><name><surname>Shyamsundar</surname><given-names>M</given-names></name><name><surname>McDowell</surname><given-names>C</given-names></name><name><surname>O&#x02019;Kane</surname><given-names>CM</given-names></name><name><surname>Elborn</surname><given-names>JS</given-names></name><name><surname>McAuley</surname><given-names>DF</given-names></name></person-group><article-title>A randomized clinical trial of hydroxymethylglutaryl-coenzyme A reductase inhibition for acute lung injury (The HARP Study)</article-title><source>Am J Resp Crit Care Med</source><year>2011</year><volume>183</volume><issue>5</issue><fpage>620</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1164/rccm.201003-0423OC</pub-id><pub-id pub-id-type="pmid">20870757</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Annecke</surname><given-names>T</given-names></name><name><surname>Chappell</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Jacob</surname><given-names>M</given-names></name><name><surname>Welsch</surname><given-names>U</given-names></name><name><surname>Sommerhoff</surname><given-names>CP</given-names></name><name><surname>Rehm</surname><given-names>M</given-names></name><name><surname>Conzen</surname><given-names>PF</given-names></name><name><surname>Becker</surname><given-names>BF</given-names></name></person-group><article-title>Sevoflurane preserves the endothelial glycocalyx against ischaemia-reperfusion injury</article-title><source>Br J Anaesth</source><year>2010</year><volume>104</volume><issue>4</issue><fpage>414</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1093/bja/aeq019</pub-id><pub-id pub-id-type="pmid">20172938</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matute-Bello</surname><given-names>G</given-names></name><name><surname>Frevert</surname><given-names>G</given-names></name><name><surname>Martin</surname><given-names>T</given-names></name></person-group><article-title>Animal models of acute lung injury</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2008</year><volume>295</volume><issue>3</issue><fpage>L379</fpage><lpage>L399</lpage><pub-id pub-id-type="doi">10.1152/ajplung.00010.2008</pub-id><pub-id pub-id-type="pmid">18621912</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pararajasingam</surname><given-names>R</given-names></name><name><surname>Nicholson</surname><given-names>ML</given-names></name><name><surname>Bell</surname><given-names>PRF</given-names></name><name><surname>Sayers</surname><given-names>RD</given-names></name></person-group><article-title>Non-cardiogenic pulmonary oedema in vascular surgery</article-title><source>Eur J Vasc Endovasc Surg</source><year>1999</year><volume>17</volume><fpage>93</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1053/ejvs.1998.0750</pub-id><pub-id pub-id-type="pmid">10063402</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nathan</surname><given-names>DP</given-names></name><name><surname>Brinster</surname><given-names>CJ</given-names></name><name><surname>Jackson</surname><given-names>BM</given-names></name><name><surname>Wang</surname><given-names>GJ</given-names></name><name><surname>Carpenter</surname><given-names>JP</given-names></name><name><surname>Fairman</surname><given-names>RM</given-names></name><name><surname>Woo</surname><given-names>EY</given-names></name></person-group><article-title>Predictors of decreased short- and long-term survival following open abdominal aortic aneurysm repair in a large contemporary series</article-title><source>J Vasc Surg</source><year>2011</year><volume>54</volume><issue>5</issue><fpage>1237</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.jvs.2011.05.028</pub-id><pub-id pub-id-type="pmid">21840157</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meduri</surname><given-names>GU</given-names></name><name><surname>Healdey</surname><given-names>S</given-names></name><name><surname>Kohler</surname><given-names>G</given-names></name><name><surname>Stentz</surname><given-names>F</given-names></name><name><surname>Tolley</surname><given-names>E</given-names></name><name><surname>Umberger</surname><given-names>R</given-names></name><name><surname>Leeper</surname><given-names>R</given-names></name></person-group><article-title>Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS</article-title><source>Chest</source><year>1995</year><volume>107</volume><fpage>1062</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.1378/chest.107.4.1062</pub-id><pub-id pub-id-type="pmid">7705118</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gosling</surname><given-names>P</given-names></name><name><surname>Sanghera</surname><given-names>K</given-names></name><name><surname>Dickson</surname><given-names>G</given-names></name></person-group><article-title>Generalized vascular permeability and pulmonary function in patients following serious trauma</article-title><source>J Trauma</source><year>1994</year><volume>36</volume><fpage>477</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1097/00005373-199404000-00002</pub-id><pub-id pub-id-type="pmid">8158705</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullan</surname><given-names>BA</given-names></name><name><surname>Ennis</surname><given-names>CN</given-names></name><name><surname>Fee</surname><given-names>HJP</given-names></name><name><surname>Young</surname><given-names>IS</given-names></name><name><surname>McCance</surname><given-names>DR</given-names></name></person-group><article-title>Pretreatment with intravenous ascorbic acid preserves endothelial function during acute hyperglycaemia</article-title><source>Clin Exp Pharmacol Physiol</source><year>2005</year><volume>32</volume><issue>5&#x02013;6</issue><fpage>340</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1681.2005.04193.x</pub-id><pub-id pub-id-type="pmid">15854139</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullan</surname><given-names>BA</given-names></name><name><surname>Ennis</surname><given-names>CN</given-names></name><name><surname>Fee</surname><given-names>HJP</given-names></name><name><surname>Young</surname><given-names>IS</given-names></name><name><surname>McCance</surname><given-names>DR</given-names></name></person-group><article-title>Protective effects of ascorbic acid on arterial hemodynamics during acute hyperglycemia</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2004</year><volume>287</volume><fpage>1262</fpage><lpage>1268</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00153.2003</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>SC</given-names></name><name><surname>Sauter</surname><given-names>G</given-names></name><name><surname>Preyer</surname><given-names>M</given-names></name><name><surname>Poerner</surname><given-names>T</given-names></name><name><surname>Kempf</surname><given-names>VA</given-names></name><name><surname>Risler</surname><given-names>T</given-names></name><name><surname>Brehm</surname><given-names>BR</given-names></name></person-group><article-title>Influence of nebivolol and metoprolol on inflammatory mediators in human coronary endothelial or smooth muscle cells. Effects on neointima formation after balloon denudation in carotid arteries of rats treated with nebivolol</article-title><source>Cell Physiol Biochem</source><year>2007</year><volume>19</volume><issue>1&#x02013;4</issue><fpage>129</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1159/000099201</pub-id><pub-id pub-id-type="pmid">17310107</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rehm</surname><given-names>M</given-names></name><name><surname>Bruegger</surname><given-names>D</given-names></name><name><surname>Christ</surname><given-names>F</given-names></name><name><surname>Conzen</surname><given-names>P</given-names></name><name><surname>Thiel</surname><given-names>M</given-names></name><name><surname>Jacob</surname><given-names>M</given-names></name><name><surname>Chappell</surname><given-names>D</given-names></name><name><surname>Stoeckelhuber</surname><given-names>M</given-names></name><name><surname>Welsch</surname><given-names>U</given-names></name><name><surname>Reichart</surname><given-names>B</given-names></name><name><surname>Peter</surname><given-names>K</given-names></name><name><surname>Becker</surname><given-names>BF</given-names></name></person-group><article-title>Shedding of the endothelial glycocalyx in patients undergoing major vascular surgery with global and regional ischemia</article-title><source>Circulation</source><year>2007</year><volume>116</volume><fpage>1896</fpage><lpage>1906</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.684852</pub-id><pub-id pub-id-type="pmid">17923576</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maurus</surname><given-names>CF</given-names></name><name><surname>Schmidt</surname><given-names>D</given-names></name><name><surname>Schneider</surname><given-names>MKG</given-names></name><name><surname>Turina</surname><given-names>MI</given-names></name><name><surname>Seebach</surname><given-names>JD</given-names></name><name><surname>Zund</surname><given-names>G</given-names></name></person-group><article-title>Hypoxia and reoxygenation do not upregulate adhesion molecules and natural killer cell adhesion on human endothelial cells in vitro</article-title><source>Eur J Cardiothorac Surg</source><year>2003</year><volume>23</volume><fpage>976</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1016/S1010-7940(03)00146-5</pub-id><pub-id pub-id-type="pmid">12829075</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindsay</surname><given-names>TF</given-names></name><name><surname>Luo</surname><given-names>XP</given-names></name><name><surname>Lehotay</surname><given-names>DC</given-names></name><name><surname>Rubin</surname><given-names>BB</given-names></name><name><surname>Anderson</surname><given-names>M</given-names></name><name><surname>Walker</surname><given-names>PM</given-names></name><name><surname>Romaschin</surname><given-names>A</given-names></name></person-group><article-title>Ruptured abdominal aortic aneurysm, a "two-hit" ischemia/reperfusion injury: Evidence from an analysis of oxidative products</article-title><source>J Vasc Surg</source><year>1999</year><volume>30</volume><fpage>219</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/S0741-5214(99)70131-X</pub-id><pub-id pub-id-type="pmid">10436441</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papalambros</surname><given-names>E</given-names></name><name><surname>Sigala</surname><given-names>F</given-names></name><name><surname>Georgopoulos</surname><given-names>S</given-names></name><name><surname>Parakevas</surname><given-names>KI</given-names></name><name><surname>Anreadou</surname><given-names>I</given-names></name><name><surname>Menenakos</surname><given-names>X</given-names></name><name><surname>Sigalas</surname><given-names>P</given-names></name><name><surname>Papalambros</surname><given-names>AL</given-names></name><name><surname>Vourliotakis</surname><given-names>G</given-names></name><name><surname>Giannopoulos</surname><given-names>A</given-names></name><name><surname>Bakoyiannis</surname><given-names>C</given-names></name><name><surname>Bastounis</surname><given-names>C</given-names></name><name><surname>Bastounis</surname><given-names>E</given-names></name></person-group><article-title>Malondialdehyde as an indicator of oxidative stress during abdominal aortic aneurysm repair</article-title><source>Angiology</source><year>2007</year><volume>58</volume><issue>4</issue><fpage>477</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1177/0003319707305246</pub-id><pub-id pub-id-type="pmid">17875961</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanaoka</surname><given-names>Y</given-names></name><name><surname>Inagaki</surname><given-names>E</given-names></name><name><surname>Hamanaka</surname><given-names>S</given-names></name><name><surname>Masaki</surname><given-names>H</given-names></name><name><surname>Tanemoto</surname><given-names>K</given-names></name></person-group><article-title>Analysis of Reactive Oxygen Metabolites (ROMs) after Cardiovascular Surgery as a Marker of Oxidative Stress</article-title><source>Acta Med Okayama</source><year>2010</year><volume>64</volume><issue>5</issue><fpage>323</fpage><lpage>330</lpage><pub-id pub-id-type="pmid">20975766</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crimi</surname><given-names>E</given-names></name><name><surname>Liguori</surname><given-names>A</given-names></name><name><surname>Condorelli</surname><given-names>M</given-names></name><name><surname>Cioffi</surname><given-names>M</given-names></name><name><surname>Astuto</surname><given-names>M</given-names></name><name><surname>Bontempo</surname><given-names>P</given-names></name><name><surname>Pignalosa</surname><given-names>O</given-names></name><name><surname>Vietri</surname><given-names>MT</given-names></name><name><surname>Molinari</surname><given-names>AM</given-names></name><name><surname>Sica</surname><given-names>V</given-names></name><name><surname>Della Corte</surname><given-names>F</given-names></name><name><surname>Napoli</surname><given-names>C</given-names></name></person-group><article-title>The Beneficial Effects of Antioxidant Supplementation in Enteral Feeding in Critically Ill Patients: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial</article-title><source>Anesth Analg</source><year>2004</year><volume>99</volume><fpage>857</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1213/01.ANE.0000133144.60584.F6</pub-id><pub-id pub-id-type="pmid">15333422</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richelle</surname><given-names>M</given-names></name><name><surname>Turini</surname><given-names>ME</given-names></name><name><surname>Guidoux</surname><given-names>R</given-names></name><name><surname>Tavazzi</surname><given-names>I</given-names></name><name><surname>Metairon</surname><given-names>S</given-names></name><name><surname>Fay</surname><given-names>LB</given-names></name></person-group><article-title>Urinary isoprostane excretion is not confounded by the lipid content of the diet</article-title><source>FEBS Lett</source><year>1999</year><volume>459</volume><fpage>259</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/S0014-5793(99)01259-4</pub-id><pub-id pub-id-type="pmid">10518031</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halliwell</surname><given-names>B</given-names></name><name><surname>Whiteman</surname><given-names>M</given-names></name></person-group><article-title>Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean?</article-title><source>Br J Pharmacol</source><year>2004</year><volume>142</volume><fpage>231</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0705776</pub-id><pub-id pub-id-type="pmid">15155533</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>H</given-names></name><name><surname>Porter</surname><given-names>N</given-names></name></person-group><article-title>Specificity of the ferrous oxidation of xylenol orange assay: analysis of autoxidation products of cholesteryl arachidonate</article-title><source>Anal Biochem</source><year>2003</year><volume>313</volume><issue>2</issue><fpage>319</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1016/S0003-2697(02)00621-8</pub-id><pub-id pub-id-type="pmid">12605870</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>DM</given-names></name><name><surname>Raman</surname><given-names>S</given-names></name><name><surname>McEneny</surname><given-names>J</given-names></name><name><surname>Young</surname><given-names>IS</given-names></name><name><surname>Parham</surname><given-names>KL</given-names></name><name><surname>Hullin</surname><given-names>DA</given-names></name><name><surname>Davies</surname><given-names>B</given-names></name><name><surname>McKeeman</surname><given-names>G</given-names></name><name><surname>McCord</surname><given-names>JM</given-names></name><name><surname>Lewis</surname><given-names>MH</given-names></name></person-group><article-title>Vitamin C prophylaxis promotes oxidative lipid damage during surgical ischemia&#x02013;reperfusion</article-title><source>Free Radic Biol Med</source><year>2006</year><volume>40</volume><fpage>591</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2005.09.024</pub-id><pub-id pub-id-type="pmid">16458189</pub-id></element-citation></ref></ref-list></back></article>